Skip to main content
J

Jilin Aodong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000623 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 4 across all filing types
Latest filing 2026-04-17 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000623

About Jilin Aodong Pharmaceutical Group Co., Ltd.

https://www.jlaod.com

Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacturing, and distribution of therapeutic products, focusing on Traditional Chinese Medicine (TCM), chemical drugs, and health supplements. The product portfolio encompasses cardiovascular medications, gastrointestinal treatments, and various specialized injections and capsules. Notable offerings include the "Anxin" series and other proprietary formulations designed for chronic disease management. The organization prioritizes the modernization of traditional formulas through advanced extraction, purification, and quality control technologies. It maintains extensive production facilities and a dedicated research infrastructure to support product innovation and safety. The company provides medical solutions across multiple therapeutic areas, aiming to bridge traditional healing methodologies with contemporary clinical standards for a diverse patient population.

Recent filings

Filing Released Lang Actions
2025年度独立董事述职报告（李鹏）
Governance Information Classification · 1% confidence The document is a formal annual performance report (述职报告) by an independent director, detailing board and committee attendance, oversight activities, governance compliance, and duties under corporate governance rules. It is not an earnings release, financial report, proxy solicitation, or simple announcement. Instead, it falls under governance disclosures about board structure, duties, and governance practices. Therefore it is best classified as Governance Information (CGR).
2026-04-17 Chinese
2025年度社会责任报告
Environmental & Social Information Classification · 1% confidence The document is titled as a “2025年度社会责任报告” (2025 Annual Social Responsibility Report) and contains detailed disclosures on the company’s ESG performance including governance, employee rights, environmental protection, supplier and customer rights, and community engagement. It follows sustainability reporting guidelines, spans over 17,000 characters, and represents a full ESG report rather than a brief announcement or excerpt. Therefore, it clearly fits the Environmental & Social Information category.
2026-04-17 Chinese
2025年度独立董事述职报告（梁毕明-已离任）
Governance Information Classification · 1% confidence The document is an independent director’s annual performance report (“独立董事述职报告”) describing board attendance, committee work, governance oversight, audit committee activities, and compliance with corporate governance rules. It is not an earnings release, financial report, or shareholder vote announcement, but rather a corporate governance disclosure relating to board practices and director duties. This aligns with the ‘Governance Information’ category.
2026-04-17 Chinese
关于2025年度计提资产减值准备的公告
Regulatory Filings Classification · 1% confidence The document is an exchange announcement by a Shenzhen‐listed company regarding the 2025 asset impairment provision. It describes accounting policy basis, the amounts, and board approval procedures; it is not a full annual or interim report, not an earnings release or capital raising, and does not fit any specialized category (e.g., M&A, director dealings, dividend notice). Therefore, it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-17 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.